Compare stocks

Pentixapharm Holding AG is a clinical-stage biopharmaceutical company specializing in the development of targeted radiopharmaceuticals for diagnostic and therapeutic applications. Its core products include PentixaFor, a Gallium-68-based tracer for diagnosing hematological and solid tumors, and PentixaTher, a Yttrium-90-based therapeutic agent for treating non-Hodgkin lymphomas. Founded in 2019 and headquartered in Berlin, Germany, the company operates additional offices in Würzburg. In July 2024, Pentixapharm acquired Glycotope's target discovery business, enhancing its pipeline with preclinical antibodies against multiple oncology targets. The company's strategic focus on CXCR4 ligand-based radiopharmaceuticals positions it to address a range of cancers and other diseases. (,)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.